Search hospitals
>
California
>
Sacramento
University of California Davis Comprehensive Cancer Center
Claim this profile
Sacramento, California 95817
Global Leader in Lung Cancer
Global Leader in Cancer
Conducts research for Breast Cancer
Conducts research for Solid Tumors
Conducts research for Pancreatic Cancer
870 reported clinical trials
39 medical researchers
Summary
University of California Davis Comprehensive Cancer Center is a medical facility located in Sacramento, California. This center is recognized for care of Lung Cancer, Cancer, Breast Cancer, Solid Tumors, Pancreatic Cancer and other specialties. University of California Davis Comprehensive Cancer Center is involved with conducting 870 clinical trials across 790 conditions. There are 39 research doctors associated with this hospital, such as Marcio H. Malogolowkin, Edward J. Kim, Jonathan W. Riess, and Mamta Parikh.
Area of expertise
Lung Cancer
University of California Davis Comprehensive Cancer Center has run 165 trials for Lung Cancer. Some of their research focus areas include:
Cancer
University of California Davis Comprehensive Cancer Center has run 124 trials for Cancer. Some of their research focus areas include:
Top PIs
Marcio H. Malogolowkin
University of California Davis Comprehensive Cancer Center
8 years of reported clinical research
Edward J. Kim
University of California Davis Comprehensive Cancer Center
2 years of reported clinical research
Jonathan W. Riess
University of California Davis Comprehensive Cancer Center
6 years of reported clinical research
Mamta Parikh
University of California Davis Comprehensive Cancer Center
5 years of reported clinical research
Clinical Trials running at University of California Davis Comprehensive Cancer Center
Breast Cancer
Lung Cancer
Skin Cancer
Ovarian Cancer
Multiple Myeloma
Prostate Cancer
Breast cancer
Kidney Cancer
Cancer
Testicular cancer
Carvedilol
for Preventing Heart Problems in HER2 Positive Breast Cancer
This trial has two cohorts of patients with human epidermal growth factor receptor (HER)-2-positive breast cancer that has spread to other places in the body. All patients must be receiving trastuzumab-based treatment. Both cohorts are being observed for cardiac toxicity. The largest cohort (currently open to accrual) is observational, and contains patients who are taking a beta blocker, ACE inhibitor, or ARB as well as their trastuzumab-based treatment. The goal is to understand how common cardiac problems are in this group of patients at high risk. The smaller cohort (currently closed to accrual) is randomized. Patients in this second cohort are randomized to either carvedilol or no treatment, with the goal of seeing whether carvedilol (used to treat heart failure and high blood pressure) may prevent the heart from side effects of chemotherapy.
Recruiting
2 awards
Phase 3
23 criteria
Low Dose Tamoxifen
for Breast Cancer
This phase III trial compares the effect of low dose tamoxifen to usual hormonal therapy, including aromatase inhibitors, in treating post-menopausal women with hormone positive, HER2 negative early stage breast cancer. Tamoxifen is in a class of medications known as antiestrogens. It blocks the activity of estrogen (a female hormone) in the breast. This may stop the growth of some breast tumors that need estrogen to grow. Aromatase inhibitors, such as anastrozole, letrozole, and exemestane, prevent the formation of estradiol, a female hormone, by interfering with an aromatase enzyme. Aromatase inhibitors are used as a type of hormone therapy to treat postmenopausal women with hormone-dependent breast cancer. Giving low dose tamoxifen may be more effective compared to usual hormone therapy in treating post-menopausal women with hormone-positive, HER2 negative early stage breast cancer.
Recruiting
2 awards
Phase 3
8 criteria
HER2-Targeted Therapy
for Breast Cancer
This phase III trial compares 6 months of human epidermal growth factor receptor 2 (HER2)-targeted therapy to 12 months of HER2-targeted therapy for the treatment of HER2-positive (+) breast cancer in patients that had a pathologic complete response (pCR) after preoperative (neoadjuvant) chemotherapy with trastuzumab. Trastuzumab and pertuzumab are monoclonal antibodies and forms of targeted therapy that attach to a receptor protein called HER2. HER2 is found on some cancer cells. When trastuzumab or pertuzumab attach to HER2, the signals that tell the cells to grow are blocked and the tumor cell may be marked for destruction by the body's immune system. Giving 6 months of HER2-targeted therapy may work better than giving 12 months for the treatment of HER2+ breast cancer in patients that had a pCR after neoadjuvant chemotherapy with trastuzumab.
Recruiting
2 awards
Phase 3
5 criteria
Similar Hospitals nearby
Frequently asked questions
What kind of research happens at University of California Davis Comprehensive Cancer Center?
University of California Davis Comprehensive Cancer Center is a medical facility located in Sacramento, California. This center is recognized for care of Lung Cancer, Cancer, Breast Cancer, Solid Tumors, Pancreatic Cancer and other specialties. University of California Davis Comprehensive Cancer Center is involved with conducting 870 clinical trials across 790 conditions. There are 39 research doctors associated with this hospital, such as Marcio H. Malogolowkin, Edward J. Kim, Jonathan W. Riess, and Mamta Parikh.
Where is University of California Davis Comprehensive Cancer Center located?
**UC Davis Comprehensive Cancer Center** - **Address:** 2279 45th Street, Suite 1600, Sacramento, CA 95817. - **Drop-off:** Main entrance on 45th Street. - **Parking:** Available in Lot 4, behind the Cancer Center.
Who should I call to ask about financial aid or insurance network?
**University of California Davis Comprehensive Cancer Center - Financial Assistance and Insurance Inquiries** - **Contact for Financial Assistance:** Reach out at 916-734-2293 (4-2293 on a hospital phone) from 8 a.m. to 4 p.m. or via email at hs-patientbilling@ucdavis.edu. - **Insurance-Related Inquiries:** Use the same contact details as for financial assistance. - **Supportive Oncology Contact:** Silvia Molina is available at 916-734-0461 or scmolina@ucdavis.edu for support.
What insurance does University of California Davis Comprehensive Cancer Center accept?
The University of California Davis Comprehensive Cancer Center accepts a wide range of health insurance plans, including Medicare, Medi-Cal, and most major health plans and insurance. Patients should contact the New Patient Referral Office at 916-703-5210 or 800-362-5566 to confirm if their specific insurance plan is accepted. It's crucial to verify with both the patient's insurance provider and the cancer center about prior authorization for services and potential charges not covered by insurance.
What awards or recognition has University of California Davis Comprehensive Cancer Center received?
The UC Davis Comprehensive Cancer Center, located in Sacramento, California, is recognized by the National Cancer Institute for its significant contributions to cancer research and patient care, receiving over $100 million in research funding annually. As an integral part of the UC Davis Medical Center, it provides access to more than 150 clinical trials and involves over 280 scientists in research programs that focus on biomedical technology, molecular oncology, and addressing cancer health disparities.
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.